The thought on everyone's mind when looking at Amarin (AMRN -1.98%) as an investor right now is: What approach is the company going to take in commercializing its new hypertriglyceridemia drug, Vascepa? Many people consider the company a potential acquisition target; others thought it would seek a partnership before going forward. But after the release of yesterday's conference call, the evidence might suggest that it plans to commercialize Vascepa on its own, an option that previously had some investors a little apprehensive. Motley Fool health care analyst Max Macaluso talks in this video about his take on Amarin's strategy going forward and why the CEO's words were well-received by the market.
Free Article
Could Amarin Reject a Buyout?
By Max Macaluso and Brenton Flynn
–
Nov 9, 2012 at 12:34PM
NASDAQ: AMRN
Amarin Plc
Market Cap
$350M
Today's Change
(-1.98%) -$0.02
Current Price
$0.84
Price as of December 11, 2023, 11:55 a.m. ET
What did the market think about Amarin's Q3 update?
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.